Genetic Mapping of a Highly Variable Norovirus GII.4 Blockade Epitope: Potential Role in Escape from Human Herd Immunity
- 15 January 2012
- journal article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 86 (2), 1214-1226
- https://doi.org/10.1128/jvi.06189-11
Abstract
Noroviruses account for 96% of viral gastroenteritis cases worldwide, with GII.4 strains responsible >80% of norovirus outbreaks. Histo-blood group antigens (HBGAs) are norovirus binding ligands, and antigenic and preferential HBGA binding profiles vary over time as new GII.4 strains emerge. The capsid P2 subdomain facilitates HBGA binding, contains neutralizing antibody epitopes, and likely evolves in response to herd immunity. To identify amino acids regulating HBGA binding and antigenic differences over time, we created chimeric virus-like particles (VLPs) between the GII.4-1987 and GII.4-2006 strains by exchanging amino acids in putative epitopes and characterized their antigenic and HBGA binding profiles using anti-GII.4-1987 and -2006 mouse monoclonal antibodies (MAbs) and polyclonal sera, 1988 outbreak human sera, and synthetic HBGAs. The exchange of amino acids 393 to 395 between GII.4-1987 and GII.4-2006 resulted in altered synthetic HBGA binding compared to parental strains. Introduction of GII.4-1987 residues 294, 297 to 298, 368, and 372 (epitope A) into GII.4-2006 resulted in reactivity with three anti-GII.4-1987 MAbs and reduced reactivity with four anti-GII.4-2006 MAbs. The three anti-GII.4-1987 MAbs also blocked chimeric VLP-HBGA interaction, while an anti-GII.4-2006 blocking antibody did not, indicating that epitope A amino acids comprise a potential neutralizing epitope for GII.4-1987 and GII.4-2006. We also tested GII.4-1987-immunized mouse polyclonal sera and 1988 outbreak human sera for the ability to block chimeric VLP-HBGA interaction and found that epitope A amino acids contribute significantly to the GII.4-1987 blockade response. Our data provide insights that help explain the emergence of new GII.4 epidemic strains over time, may aid development of norovirus therapeutics, and may help predict the emergence of future epidemic strains.Keywords
This publication has 48 references indexed in Scilit:
- A dimensionless number for understanding the evolutionary dynamics of antigenically variable RNA virusesProceedings. Biological sciences, 2011
- Economic value of norovirus outbreak control measures in healthcare settingsClinical Microbiology & Infection, 2011
- Chimpanzees as an animal model for human norovirus infection and vaccine developmentProceedings of the National Academy of Sciences of the United States of America, 2010
- Serological Correlate of Protection against Norovirus‐Induced GastroenteritisThe Journal of Infectious Diseases, 2010
- Characterization of a discontinuous epitope of the HIV envelope protein gp120 recognized by a human monoclonal antibody using chemical modification and mass spectrometric analysisJournal of the American Society for Mass Spectrometry, 2010
- Monoclonal antibodies specific for discontinuous epitopes direct refolding of influenza A virus hemagglutininMolecular Immunology, 2010
- Elucidation of strain-specific interaction of a GII-4 norovirus with HBGA receptors by site-directed mutagenesis studyVirology, 2008
- Structural Basis for the Recognition of Blood Group Trisaccharides by NorovirusJournal of Virology, 2007
- Epochal Evolution Shapes the Phylodynamics of Interpandemic Influenza A (H3N2) in HumansScience, 2006
- Multiple sequence alignment with the Clustal series of programsNucleic Acids Research, 2003